Collaborative and Other Relationships (Tables)

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:




After LUNSUMIO Approval until the First Threshold Date	37.5	%
After First Threshold Date until the Second Threshold Date	35.0	%
After Second Threshold Date	30.0	%

Pretax profit sharing formula

Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:



Until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Summary of activity related to the UCB collaboration

A summary of development expense related to the UCB collaboration agreement is as follows:


	For the Three Months Ended March 31,
(In millions)	2024		2023
Total UCB collaboration development expense	$	16.6	$	18.3
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	8.3		9.2

Summary of Activity Related to Denali Therapeutics Collaboration

A summary of development expense related to the Denali collaboration is as follows:


	For the Three Months Ended March 31,
(In millions)	2024		2023
Total Denali collaboration development expense	$	14.2	$	16.6
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	8.5		10.0

Summary of Activity Related to BAN2401 and Elenbecestat Collaboration


	For the Three Months Ended March 31,
(In millions)	2024		2023
Total development expense incurred by the collaboration related to the advancement of LEQEMBI	$	87.3	$	107.9
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	43.6		54.0
Total sales and marketing expense incurred by the LEQEMBI Collaboration	173.9		10.5
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income	86.9		5.3

Summary of Activity Related to Sage Therapeutics

A summary of development and sales and marketing expense related to the Sage collaboration is as follows:


	For the Three Months Ended March 31,
(In millions)	2024		2023
Total Sage collaboration development expense	$	11.6	$	34.8
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	5.8		17.4
Total sales and marketing expense incurred by the Sage collaboration	27.6		38.2
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income	13.8		19.1